The present invention is directed to a pharmaceutical dosage form exhibiting improved stabilization of an angiotensin-converting-enzyme inhibitor (ACE inhibitor) present therein. The dosage form comprises the angiotensin-converting-enzyme inhibitor and a stabilizer and has at least two separate portions, wherein the angiotensin-converting-enzyme inhibitor is contained in one of the portions and the stabilizer compound is contained in another portion. The dosage form can make use of an intra- granular/extra-granular structure, wherein preferably the ACE inhibitor compound is placed within the intra-granular portion and the stabilizer is placed in the extra-granular portion, or vice versa the stabilizer is placed within the intra-granular portion and the ACE inhibitor compound is placed in the extra-granular portion, and further alternatively when adopting a core/shell structure, such that the ACE inhibitor is contained in the core and the stabilizer compound is contained in a surrounding layer, or the ACE inhibitor is contained in a surrounding layer and the stabilizer compound is contained in the core, wherein optionally an intermediate layer, such as a layer basically formed from a film-forming polymer, can be provided between the core and the surrounding layer.
